R&D
- Aesthetics
Localized Fat Reduction, Cellulite,
Hyperpigmentation, Skin Aging
- Therapeutics
Dercum's Disease, Osteoarthritis, Central Obesity
-
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
-
CBL-514
-
CBA-539
-
CBF-520
-
CBL-539, a long-acting injectable product, is designed for a more efficacious and safe treatment for refractory melasma by inhibiting melanin production. Besides, CBL-539 was evidenced that could recover skin elasticity by increasing collagen production.
Conditions/Indications： Hyperpigmentation, Skin aging
About Caliway
In Caliway, we are driven to breakthrough drug discovery of novel small-molecule therapeutics for medical aesthetics and inflammatory disease. By developing innovative drugs, we aim to provide new treatment options for the indications in which clinical needs remain unmet.
-
ADVANTAGE
Well-Experimented Team of Experts
Caliway's research team comprises experts with deep knowledge and experience in drug discovery, business development, and regulatory affairs. We develop innovative new strategies with high safety to address medical conditions with no effective treatments available. -
ADVANTAGE
Target Emerging Markets
In Caliway, the diseases we are targeted on affect millions of people, often in their most productive years. We are on a mission to combine science, medicine, and advocacy with improving people's lives suffering from illnesses or life-threatening diseases. -
ADVANTAGE
Global IP Protection
We have exclusive rights to benefit from the commercial use of our products, such as producing, selling, and exporting worldwide.
-
04
2026
Caliway’s Asia-Pacific Phase 2 Study CBL-0206 Approved by Australia’s HREC to Proceed, Officially Advancing Asia-Pacific Clinical Strategy
Caliway’s Asia-Pacific Phase 2 study of CBL-514 for reduction of abdominal subcutaneous fat, CBL-0206, has received approval from Australia’s HREC to proceed, officially advancing the Company’s Asia-Pacific clinical strategy.
-
04
2026
Caliway Completes U.S. FDA IND Submission for SUPREME-02, the Second Global Pivotal Phase 3 Study of CBL-514. Advancing Dual-Track Global Phase 3 Clinical Development
Caliway has completed the U.S. FDA IND submission for SUPREME-02, the second global multi-national, multi-center pivotal Phase 3 study of CBL-514 for reduction of abdominal subcutaneous fat, progressing on schedule according to the Company’s development plan.
-
04
2026
Caliway's Fat Reduction Drug CBL-514 Phase 2 Clinical Results Accepted by ASJ. CBL-0204's Demonstrated Efficacy and Safety Gain Further Academic Recognition
Clinical results from CBL-0204 Phase 2b, a study of its first-in-class large-area localized fat reduction drug candidate, CBL-514, for subcutaneous fat reduction, have been accepted by the Aesthetic Surgery Journal (ASJ), a globally recognized authority in aesthetic medicine.
-
03
2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association’s 2026 Scientific Sessions
Preclinical research on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association’s 2026 Scientific Sessions.The presentation will be delivered by W. Timothy Garvey, MD, a globally recognized authority in obesity and metabolic medicine and a scientific advisor to Caliway.
-
03
2026
Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
Preclinical data on Caliway’s fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for oral presentation at the European Congress on Obesity (ECO 2026). The presentation will be delivered by Arya M. Sharma, MD, Caliway’s scientific advisor and a globally recognized authority in obesity medicine, who will discuss CBL-514’s fat-reduction efficacy, differentiated mechanism, and potential scientific value as a complementary approach to current weight-loss therapies.
